Skip to main content

Table 1 Patient demographics and clinical characteristics of de novo prostate cancer patients with bone metastases (N = 16,643)

From: Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients

Characteristics

Level

Number (%)

Age at diagnosis

Mean ± SD

71.41 ± 11.318

Median (range)

71 (34–105)

≤ 70

8079 (48.5%)

> 70

8564 (51.5%)

Race

White

12,367 (74.3%)

Black

303 (18.2%)

Asian or Pacific Islander

989 (5.9%)

Others/unknown

257 (1.5%)

Marital status

Married

8987 (54.0%)

Unmarried

6542 (39.3%)

Unknown

1114 (6.7%)

Tumor grade

Well differentiated

96 (0.6%)

Moderately differentiated

861 (5.2%)

Poorly differentiated

9097 (54.6%)

Undifferentiated

87 (0.5%)

Unknown

6502 (39.1%)

PSA

≤ 10 ng/ml

1271 (7.6%)

10–20 ng/ml

1240 (7.4%)

20–50 ng/ml

2037 (12.2%)

> 50 ng/ml

10,336 (62.1%)

Unknown

1759 (10.6%)

Gleason

≤ 6

219 (1.3%)

3 + 4

536 (3.2%)

4 + 3

885 (5.3%)

8–10

8052 (48.4%)

Unknown

6951 (41.8%)

Metastatic sites

Bone-only

14,872 (89.4%)

Bone and lung

976 (5.9%)

Bone and liver

414 (2.5%)

Bone and brain

126 (0.8%)

Bone and ≥ 2 other sites

255 (1.3%)

Surgery

Yes

1593 (9.6%)

No/unknown

15,085 (90.4%)

Radiotherapy

Yes

3765 (22.6%)

No/unknown

12,878 (77.4%)

Chemotherapy

Yes

2216 (13.3%)

No/unknown

14,427 (86.7%)

  1. PSA prostate specific antigen